IXICO plc Board Changes

September 16, 2016

London, UK, 16 September 2016: IXICO plc (Ticker: IXI), the brain health company, today announces the following changes to the Board, all of which take immediate effect:

Dr Andy Richards has elected to step down from the Board to focus on his other commitments. Andy has been Chairman of IXICO since 2009 and has guided the Company through its formative years. In particular, Andy’s vision and enthusiasm for the deployment of technological innovations in the healthcare industry to realise the potential for digital healthcare has been central in developing IXICO into the business it is today.

Download full press release here


Charles Spicer has succeeded Andy as Non-Executive Chairman.  Charles was an executive Director of IXICO between July 2013 and January 2016 with a focus on corporate strategy. He became a Non-Executive Director of IXICO in January 2016.  He has a wealth of experience working for, and as advisor to, public and private companies primarily in the medtech and life science sectors. Charles is currently Chairman of an NIHR Invention for Innovation (i4i) funding panel and is also Non-Executive Chairman of PuriCore Plc, 11 Health & Technologies Limited and Creo Medical Limited.  

In addition, Mark Warne joins the Board as a Non-Executive Director.  He is Head of the Healthcare division of IP Group Plc (LSE: IPO) which, at the end of December 2015, had shareholdings in 31 companies valued at over £275 million.  Mark previously acted as the power of attorney for corporate director IP2IPO Services Limited of Optimal Medicine Limited and was instrumental in the sale of the business to IXICO. As part of that acquisition and the participation of IP Group Plc in the financing round completed in December 2015, IP Group has a 20.25% shareholding in the Company.  Mark brings a wealth of technology commercialisation experience to support IXICO through its next stage of product development and value creation.  Mark has been at IP Group since 2008 and represents it on the boards of several portfolio companies, both quoted and private.  He has extensive experience in building and growing healthcare businesses as well as in managing transactions including portfolio company IPOs, financings and M&A.  

Mark will join the Remuneration Committee which is chaired by Tim Sharpington and the Audit Committee which is chaired by John Bradshaw.  

David Brister, who joined the Board following the acquisition of Optimal Medicine Limited, stepped down as a Non-Executive Director having helped oversee the successful integration of this acquisition.

Derek Hill, Chief Executive Officer of IXICO, said:

“We are grateful to Andy Richards for the huge contribution he has made to IXICO. He set the vision for IXICO’s development into a digital healthcare company for brain health, identifying the opportunities to raise growth capital through admission onto AIM in 2013, and the acquisition of Optimal Medicine in 2015.”

Mark Warne, Non-Executive Director of IXICO and Head of Healthcare at IP Group plc, said:

“I am excited to be joining the board of IXICO and I see significant potential for it to lead in the CNS and behavioural health fields in the rapidly growing digital health market.  Its team is highly respected by industry and government for its brain health specialisation and the Company has some fantastic technologies.  I would also like to take this opportunity to thank David Brister for his recent contribution to IXICO and prior contribution as Chairman at Optimal Medicine where IP Group was a shareholder”.


IXICO plc  
Derek Hill, CEO    
Susan Lowther, CFO    

+44 20 3763 7499

Peel Hunt LLP (Nominated Adviser)    
James Steel / Oliver Jackson    

+44 20 7418 8900
FTI Consulting Limited (Investor Relations)    
Simon Conway / Mo Noonan / Matthew Moss   

 +44 20 3727 1000

Additional Information:

The following further information regarding the appointment of Mark Robert Warne, aged 41, is disclosed under Schedule 2(g) and Rule 17 of the AIM Rules for Companies:

(i)    Mark Warne is currently a director or partner of:

  • Capsant Neurotechnologies Limited

  • Cronin Group plc

  • Crysalin Limited

  • Genomics plc

  • hVIVO plc

  • Oxford CADD Limited 


(ii)    in the last five years, Mark Warne has been but is no longer a director or partner of the following companies or partnerships: 

  • 31 Howard Road Management Limited 

  • Bristol Innovations Limited 

  • Genomics Limited

  • OM France SARL

  • Optimal Medicine Inc. 

  • Oxtox Limited

(iii) in the last five years, Mark Warne has acted as a power of attorney for corporate director IP2IPO Services Limited to the following companies:

  • InhibOx Limited

  • Optimal Medicine Limited

  • Activiomics Limited

  • Ubiquigent Limited

  • Azellon Limited

  • Cronin3D Limited

  • Mode Diagnostics Limited

  • Mode Health Limited

(iv) Mark Warne holds 4,323 ordinary shares in his own name and has an indirect interest in IP2IPO’s and the NETF shareholdings in IXICO plc.

Mark Warne has confirmed that there is no other additional information to be disclosed under Schedule 2 (g) of the AIM Rules.


IXICO’s innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions.  In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes.  In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company’s brain health focus includes Alzheimer’s disease, Huntington’s disease, multiple sclerosis, behavioural health, child and adolescent mental health. More information is available on www.ixico.com